Results 301 to 310 of about 219,205 (349)
Some of the next articles are maybe not open access.
Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer.
Journal of Clinical Oncology, 2017 T. Beer, E. Kwon, C. Drake, K. Fizazi, C. Logothetis, G. Gravis, V. Ganju, J. Polikoff, F. Saad, Piotr Humanski, J. Piulats, P. González Mella, S. Ng, D. Jaeger, F. Parnis, F. Franke, J. Puente, Roman Carvajal, L. Sengeløv, M. McHenry, Arvind Varma, A. V. D. van den Eertwegh, W. Gerritsen +22 moresemanticscholar +1 more sourceAbiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study.
The Lancet Oncology, 2015 C. Ryan, Matthew R. Smith, K. Fizazi, F. Saad, P. Mulders, C. Sternberg, K. Miller, C. Logothetis, N. Shore, E. Small, J. Carles, T. Flaig, M. Taplin, C. Higano, Paul L De Souza, J. D. de Bono, T. Griffin, P. De Porre, Margaret K Yu, Y. Park, Jinhui Li, T. Kheoh, V. Naini, A. Molina, D. Rathkopf +24 moresemanticscholar +1 more source